trending Market Intelligence /marketintelligence/en/news-insights/trending/_46Kik-F1qzG-YvtMpq3BQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Riverside invests in Spanish pharmaceutical ingredient maker

Street Talk Episode 61 - Investors debate if U.S. banks have enough capital in post COVID world

You Down With PPP? Consider The Risks

Street Talk Episode 60 - You Down With PPP? Consider The Risks

Gauging Supply Chain Risk In Volatile Times

Riverside invests in Spanish pharmaceutical ingredient maker

Lower-middle-market private equity firm Riverside Partners LLC, doing business as The Riverside Co., made an undisclosed investment in Spanish active pharmaceutical ingredients producer HealthTech BioActives SL.

The transaction includes the 140 employees of HealthTech, which is a carve-out of Spain-based international pharmaceutical company Ferrer.

KPMG was carve-out and financial adviser to Riverside, with Garrigues and Advocatenkantoor Parmentier offering legal and tax counsel. A&O was a legal adviser for the financing process, while Dextra Corporate was the exclusive buy-side M&A adviser, and PWC was ESG and buy-side debt adviser. Roland Berger was commercial adviser, and financing was provided by LGT Private Debt.

Deloitte was Ferrer's financial, legal, tax and exclusive sell-side M&A adviser.